A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function.

Trial Profile

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Feb 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top